Coexpressing the IL7R with CAR-GD2 T cells activates STAT5 signaling and shows super antitumor response in metastatic neuroblastoma and glioblastoma mice model (104). Clinical trials using recombinant IL7 as monotherapy showed increases in CD4 and CD8 T cells with a decrease in Tregs in multiple cancer types (95, 121). Here, IL7R is linked to cancer.